MindMaze Therapeutics Holding SA has officially completed its business combination with NeuroX Group SA, marking a significant milestone in the development of digital treatments for neurological diseases. This merger, announced on December 15, 2025, consolidates both companies under the MindMaze Therapeutics name, creating a newly integrated entity poised to innovate in neurological care.
The completion of this business combination follows a definitive agreement signed in October 2025 and subsequent shareholder approval during an extraordinary general meeting held in November. The merger combines precision digital neurotherapeutics with pharmacological treatments and advanced technology, establishing a unique ecosystem aimed at addressing the growing challenges of neurological disorders.
Addressing Global Health Challenges
According to Olaf Blanke (MD), a board member and professor at the Swiss Federal Institute of Technology (EPFL), neurological diseases are among the leading causes of global disability. He noted, “The situation is worsening due to aging populations, with 1 in 6 people expected to develop a neurological disease, making the need for effective, scalable solutions more urgent than ever.” Blanke emphasized that traditional healthcare systems often fall short in delivering adequate therapies, leaving many patients without optimal treatment options.
MindMaze Therapeutics aims to bridge this gap by offering clinically proven neurotherapeutics to support patients’ recovery journeys across various settings, from hospitals to rehabilitation centers and home care. The company’s mission focuses on transforming neurological care through validated innovations and a commitment to enhancing patient outcomes.
Walid Hanna, Chairman of the Board of Directors, expressed optimism about the merger’s potential impact. “Today begins a new chapter for MindMaze Therapeutics,” he stated. “The company is founded on clinically validated innovation and driven by a mission to transform neurological care, addressing a critical and persistent gap in motor and cognition restorations in neurological conditions.” He highlighted the importance of advancing the precision neurotherapeutics platform to create a substantial impact at scale.
Details of the Business Combination
As part of the merger, MindMaze Therapeutics acquired NeuroX through a share exchange, in which all outstanding shares of NeuroX were contributed by its former shareholders in exchange for 140,000,000 newly issued ordinary shares of MindMaze. These shares will commence trading on the SIX Swiss Exchange today under the updated ticker symbol MMTX. Following the transaction, the total number of outstanding shares will reach 152,602,044, excluding treasury shares.
MindMaze Therapeutics is now positioned as a commercial-stage company dedicated to the development and commercialization of pioneering digital treatments for neurological diseases. The firm operates on a sophisticated platform that integrates software, sensors, and telehealth solutions, with applications in clinical and home environments. The company’s clinically validated neurotherapeutics have shown promising medico-economic outcomes for conditions such as stroke and Parkinson’s disease, and it is expanding its research and development pipeline to include other neurological conditions like multiple sclerosis and traumatic brain injury.
In addition to its focus on neurological treatments, MindMaze Therapeutics will also manage Relief Therapeutics’ existing portfolio of biopharmaceutical assets, which target rare dermatological, metabolic, and respiratory diseases.
For more information on MindMaze Therapeutics, visit their website at www.mindmazetherapeutics.com.
